DTHIB binds HSF1 directly and degrades HSF1 in the nucleus, thereby decreasing its nuclear activity and ultimately lowering its transcriptional activity in prostate cancer (Dong et al., 2020). Here, HSF1 is linked to prostate carcinoma.